Clinical Trials Sponsored by Eisai Co., Ltd.

Total 10300 results

Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Biogen
Eisai Co., Ltd.

Completed

A Study to Assess Absolute Bioavailability of Aducanumab in Healthy Volunteers

Healthy Volunteers

United States
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Abbott
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Japan
Abbott
Eisai Co., Ltd.

Completed

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Juvenile Rheumatoid Arthritis

Japan
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Abbott
Eisai Co., Ltd.; Abbott Japan Co.,Ltd

Completed

Adalimumab in Adult Japanese Subjects With Psoriasis

Psoriasis

Japan
Keio University
Eisai Co., Ltd.

Active, not recruiting

Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan

Rheumatoid Arthritis

Korea, Republic of, Taiwan, Japan
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States, Spain, France, Italy, Japan, Russian Federation, United Kingdom
Eisai Co., Ltd.
Merck Sharp & Dohme LLC

Completed

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Solid Tumors

Japan
EA Pharma Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants

Healthy Volunteers

United Kingdom
EA Pharma Co., Ltd.

Completed

A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants

Healthy Male Participants

United Kingdom
EA Pharma Co., Ltd.

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

Healthy Participants

United Kingdom
EA Pharma Co., Ltd.

Withdrawn

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants

Healthy Participants
EA Pharma Co., Ltd.

Completed

General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation

Chronic Constipation

Japan
EA Pharma Co., Ltd.

Active, not recruiting

A Study of E6011 in Participants With Active Crohn's Disease

Crohn's Disease

Czechia, Hungary, Japan, Poland, Russian Federation
EA Pharma Co., Ltd.

Completed

A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants

Healthy Male Participants

Japan
EA Pharma Co., Ltd.

Completed

A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects

Healthy Male Volunteers

Japan
EA Pharma Co., Ltd.

Completed

A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects

Japanese Healthy Adult Male Participants

Japan
University of Tokushima
Eisai Co., Ltd.

Unknown

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS (JETALS)

Amyotrophic Lateral Sclerosis

Japan
Altoida
Eisai Co., Ltd.; Ionian University

Recruiting

Diagnosis and Monitoring of Disease Progression Using Deep Neuro Signatures (DNS)

Mild Cognitive Impairment | Alzheimer's Disease

Greece
EA Pharma Co., Ltd.

Completed

A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

Crohn's Disease

Japan
EA Pharma Co., Ltd.

Completed

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis

Moderate Active Ulcerative Colitis

Japan
EA Pharma Co., Ltd.

Terminated

Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Primary Biliary Cholangitis

Japan
EA Pharma Co., Ltd.
Kissei Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

Colitis, Ulcerative

Japan
Eisai Inc.
Bliss Biopharmaceutical (Hangzhou) Co., Ltd

Recruiting

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Breast Cancer

United States
National Cancer Center, Japan
Eisai Co., Ltd.

Active, not recruiting

NCCH2006/MK010 Trial (FORTUNE Trial)

Advanced or Recurrent Solid Tumors | FGFR Gene Alterations

Japan
Drugs for Neglected Diseases
Eisai Co., Ltd.

Unknown

Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease

Chronic Chagas Disease, Indeterminate

Bolivia
National University Hospital, Singapore
Eisai Co., Ltd.

Recruiting

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Breast Cancer

Singapore
National University Hospital, Singapore
Eisai Co., Ltd.

Unknown

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

Breast Cancer

Singapore
Japan Breast Cancer Research Group
Eisai Co., Ltd.

Recruiting

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Breast Cancer

Japan
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Japan
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Intestinal Behçet's Disease

Japan
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.

Completed

Surveillance of Humira Injection in Korean Patients

Rheumatoid Arthritis | Psoriasis | Crohn's Disease | Psoriatic Arthritis | Ankylosing Spondylitis

Korea, Republic of
Eisai Pharmaceuticals India Pvt. Ltd

Completed

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Carcinoma, Hepatocellular

India
Eisai Pharmaceuticals India Pvt. Ltd

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Thyroid Neoplasms

India
Eisai Pharmaceuticals India Pvt. Ltd

Completed

A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

Epilepsy | Partial Onset Seizures

India
Emory University
National Cancer Institute (NCI); Eisai Co., Ltd.

Recruiting

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

Unresectable Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC... and other conditions

United States
Teresa Helsten, MD
Eisai Co., Ltd.

Withdrawn

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Cancer

United States
National University Hospital, Singapore
Eisai Co., Ltd.; Tan Tock Seng Hospital

Unknown

Phase II Study of Single Agent Lenvatinib

Breast Cancer

Singapore
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
National Cancer Center Hospital East
Merck Sharp & Dohme LLC; Eisai Co., Ltd.

Completed

Lenvatinib and Pembrolizumab Simultaneous Combination Study (Lenva+Pembro)

Advanced Gastric Cancer

Japan
Huons Co., Ltd.
Humedix Co., Ltd.

Unknown

To Evaluate the Efficacy and Safety of Injection With HARA as Compared to Restylane® Lidocaine in Temporary Correction of Nasolabial Folds

Nasolabial FOLD

Korea, Republic of
Asan Medical Center
Eisai Inc.; Dong-A ST Co., Ltd.; Samyang Biopharmaceuticals Corporation

Completed

Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer (EG_PG)

Metastatic Breast Cancer

Korea, Republic of
National Institute of Diabetes and Digestive and...
Eisai Co., Ltd.

Completed

Vitamin K and Bone Turnover in Postmenopausal Women

Osteoporosis

United States
NanoCarrier Co., Ltd.
Orient Europharma Co., Ltd.

Completed

NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia

Locally Advanced and Metastatic Pancreatic Cancer

Taiwan, Singapore
InventisBio Co., Ltd
InxMed (Shanghai) Co., Ltd.

Recruiting

Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

Solid Tumor

China

Clinical Trials Sponsored by Eisai Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations